Efficacy of Risperidone Orally Disintegrating Tablets Combined with Oxazepam in the Treatment of Schizophrenia

To explore the efficacy of risperidone orally disintegrating tablets combined with oxazepam in the treatment of schizophrenia.

From May 2019 to May 2021, 60 patients with schizophrenia treated in our hospital were recruited and assigned into an observation group (risperidone orally disintegrating tablets combined with oxazepam treatment) and a control group (alprazolam combined with chlorpromazine treatment) according to the random number table method. The positive and negative symptom score (PANSS), quality of life score (QOL-75), ability of daily living score (ADL), clinical efficacy, incidence of adverse reactions, and disease recurrence were compared between the two groups before and after treatment.

The PANSS scores were similar in the two groups before treatment (P > 0.05). The two groups presented a declining trend in PANSS score after treatment, whereas a remarkable lower score in the observation group was observed (P < 0.05). The QOL scores of the two groups of patients before treatment was not significantly different (P > 0.05). Both groups witnessed improvements one month and three months after treatment, with considerable improvements being obtained in the observation group (all P < 0.05). The two groups did not differ in ADL scores before treatment (P > 0.05). At 1 month and 3 months after treatment, the ADL scores of the two groups were improved, with a higher score in the observation group (P < 0.05). The observation group had a markedly higher total effective rate as compared to the control group (X ² = 5.455, P=0.020). Adverse reaction occurred in both groups, with milder results in the observation group. The recurrence rate of the two groups was not statistically different one month after treatment (P > 0.05), while two and three months after treatment, they were lower than those of the control group (all P < 0.05).

Risperidone orally disintegrating tablets combined with oxazepam shows potential in the treatment of schizophrenia by relieving patients' mental symptoms, improving quality of life and activities of daily living, and minimizing the incidence of adverse reactions.